Targeting KRAS reprograms a Treg-dominant immunosuppressive microenvironment and sensitizes KRAS-mutant gastric adenocarcinoma to CTLA-4 immunotherapy.
Sep 2026· Science China Life Sciences· 0 citations· 27 references
Medicine
TL;DR
Findings identify oncogenic KRAS as a key regulator of TGF-β-dependent immune suppression in GA and provide mechanistic insight into immune evasion within this molecular subtype.
An immunosuppressive tumor microenvironment (TME) is a hallmark of pancreatic ductal adenocarcinoma (PDAC), rendering most tumors resistant to immunotherapy approaches. Importantly, “tumor-to-stroma” crosstalk downstream of oncogenic KRAS has emerged as a major driver of immune evasion in PDAC, however the role of re...
Yuwenbin Li, M. Truitt, Dan Cao et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by oncogenic KRAS signaling and sustained by a desmoplastic, immunosuppressive microenvironment limiting therapeutic response. CD73-mediated adenosine signaling supports this immune-excluded, tumor-supportive microenvironment. Whether dual targeting of KRA...
Khadija Turabi, Urvinder Kaur Sardarni, Katherine E. Ankenbauer et al.· bioRxiv· 0 citations
Cancer cell-intrinsic epithelial-mesenchymal plasticity (EMP) drives carcinoma progression through increased intratumoral heterogeneity and an immunosuppressive tumor microenvironment (TME). Specifically, EMP activation in murine mammary carcinomas results in exclusion of CD8+ T-cells and recruitment of immunosuppressi...
Kimaya M. Bakhle, Andreas Stephanou, Sarthak Sahoo et al.· bioRxiv· 0 citations
Abstract Background KRAS-mutant lung adenocarcinoma (LUAD) shows limited benefit from immune checkpoint blockade (ICB), and the mechanisms by which oncogenic KRAS signaling promotes immune resistance remain poorly understood. Here, we sought to identify tumor-intrinsic mediators of KRAS-driven immune evasion and therap...
Yi Liu, Chen Zhang, Jia Li et al.· Journal for ImmunoTherapy of...· 0 citations
A patient-specific ex vivo organoid model is developed to define CXCL12/CXCR4-mediated immune regulation and identify additional cellular and molecular targets to enhance antitumor efficacy and demonstrate that CXCR4 inhibition enhances immune-cell infiltration and activation, modulates checkpoint expression, and promo...
I. Pellicciotta, G. Manji, A. Raufi et al.· Cancer Research· 0 citations
It is reported that, in an UVB induced Braf V600E-mutated spontaneous mouse melanoma model, p38α contributes to tumor fitness and anti-tumor immune responses, showing that p38α inhibition sensitizes tumors to anti-PD1.
Paula Granado-Martínez, K. McGrail, Roberto Orsenigo et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.